(1S,4S)-2-甲基-2,5-二氮杂双环[2.2.1]庚烷盐酸盐(1:2) | 127420-27-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: (1S,4S)-2-甲基-2,5-二氮杂双环[2.2.1]庚烷盐酸盐(1:2)
• 中文别名: 2-甲基-2,5-二氮杂二环[2.2.1]庚烷二氢溴酸盐；(1S)-2-甲基-2,5-二氮双环[2.2.1]庚烷二氢溴酸盐；(1S,4S)-2-甲基-2,5-二氮杂双环[2.2.1]二氢溴酸庚酯
• 英文名称: (1S,4S)-2-Methyl-2,5-diazabicyclo[2.2.1]heptane dihydrochloride
• 英文别名: (1S,4S)-2-methyl-2,5-diazabicyclo[2.2.1]heptane;dihydrochloride
• CAS: 127420-27-3
• 化学式: C6H14Cl2N2
• 分子量: 185.09
• InChiKey: CPKLWCPJBAELNP-USPAICOZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.51
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
  申请人：Xie Wenge

  公开号：US20050176754A1

  公开（公告）日：2005-08-11

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明涉及尼古丁乙酰胆碱受体（nAChR）配体、nAChR的激活以及与缺陷或失灵的尼古丁乙酰胆碱受体相关的疾病情况的治疗，特别是大脑的疾病情况。此外，本发明还涉及新型化合物，例如吲哚、1H-吲唑、1,2-苯并异噁唑和1,2-苯并异硫嗪，它们作为α7 nAChR亚型的配体，制备这些化合物的方法，含有这些化合物的组合物以及其使用方法。
• INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF
  申请人：XIE Wenge

  公开号：US20090088437A1

  公开（公告）日：2009-04-02

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明涉及尼古丁乙酰胆碱受体（nAChR）配体、nAChR的激活以及与缺陷或功能失调的尼古丁乙酰胆碱受体相关的疾病状态的治疗，特别是与大脑相关的疾病状态。此外，本发明涉及新型化合物，例如吲哚、1H-吲哚唑、1,2-苯并异噁唑和1,2-苯并异硫噻唑，它们作为α7 nAChR亚型的配体，制备这种化合物的方法，含有这种化合物的组合物以及使用这种化合物的方法。
• Pharmaceutical waste disposal assembly
  申请人：Stryker Corporation

  公开号：US10086416B2

  公开（公告）日：2018-10-02

  A pharmaceutical waste disposal assembly (10) for disposing of raw pharmaceutical waste includes a receiver body (19) and a first reaction agent (287). The receiver body (19) is configured to receive the pharmaceutical waste. The receiver body (19) includes a body interior wall (921A) that defines a body interior (921B). The first reaction agent (287) is positioned within the body interior (921B) so that the first reaction agent (287) contacts the body interior wall (921A) prior to receiving the pharmaceutical waste. The first reaction agent (287) chemically reacts with the pharmaceutical waste so that the pharmaceutical waste is rendered unrecoverable. The first reaction agent (287) can include at least one of a denaturant and a deterrent. Additionally, the first reaction agent (287) can include activated charcoal.

  用于处置未加工药物废物的药物废物处置组件 (10) 包括一个接收体 (19) 和一个第一反应剂 (287)。接收器主体（19）被配置为接收医药废物。接收器主体 (19) 包括限定主体内部 (921B) 的主体内壁 (921A)。第一反应剂 (287) 位于主体内部 (921B) 中，以便第一反应剂 (287) 在接收药物废料之前接触主体内壁 (921A)。第一反应剂 (287) 与药物废物发生化学反应，使药物废物无法回收。第一反应剂 (287) 可以包括变性剂和阻遏剂中的至少一种。此外，第一反应剂（287）还可以包括活性炭。
• Waste disposal system and waste receiver for receiving and disposing of pharmaceutical waste material
  申请人：Stryker Corporation

  公开号：US10940513B2

  公开（公告）日：2021-03-09

  A waste disposal system with a waste receiver for receiving pharmaceutical waste material. A locking assembly is secured to a fixed surface and actuated from a locked configuration to an unlocked configuration. A lock cylinder of the locking assembly may extend forward of a front wall of a receiver body of the waste receiver to engage a locking feature of the cover in the locked configuration. A cover retention feature may prevent axial decoupling of the cover from the receiver body. An engagement feature is moved to be disengaged from the receiver body, and the receiver body is moved away from the fixed surface to disengage the locking assembly from the cover. The cover is decoupled from the cover retention feature, and coupled with the receiver body to seal the pharmaceutical waste material. The locking assembly may be removed from a lock passageway for disposal of the waste receiver.

  一种废物处理系统，带有一个用于接收药物废料的废物接收器。一个锁定组件固定在一个固定表面上，并从锁定配置驱动到解锁配置。锁定组件的锁芯可从废物接收器的接收器主体的前壁向前延伸，以便在锁定配置中与盖子的锁定功能相啮合。盖子固定特征可防止盖子与接收器本体的轴向脱钩。移动啮合特征，使其与接收器本体脱离，接收器本体远离固定表面，使锁定组件与盖子脱离。盖子与盖子固定特征脱钩，并与接收器本体耦合，以密封药物废料。锁定组件可从锁定通道中取出，以便对废物接收器进行处置。
• 1,4-Dihydro-4-oxo-3-quinolone derivatives as selectively toxic mammalian antibacterial agents
  申请人：PFIZER INC.

  公开号：EP0421668B1

  公开（公告）日：1995-01-04